个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Su Ke[1] ; Guo Lu[2] ; Ma Wenqiong[1] ; Wang Jing[3] ; Xie Yunchuan[4] ; Rao Mingyue[1] ; Zhang Jianwen[1] ; Li Xueting[5] ; Wen Lianbin[6] ; Li Bo[7,8,9] ; Yang Xiaoli[7,8,9] ; Song Yanqiong[10] ; Huang Weihong[11] ; Chi Hao[11] ; Gu Tao[1] ; Xu Ke[1] ; Liu Yanlin[1] ; Chen Jiali[1] ; Wu Zhenying[1] ; Jiang Yi[1] ; Li Han[1] ; Zeng Hao[1] ; Wang Pan[12] ; Feng Xunjie[11] ; Chen Siyu[11] ; Yang Binbin[11] ; Jin Hongping[11] ; He Kun[3] ; Han Yunwei[1,8,9] ;
机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [2]Department of Ophthalmology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [3]Clinical Research Institute, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [4]Department of Radiology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [5]Department of Oncology, 363 Hospital, Chengdu, China. [6]Department of Geriatric Cardiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, China. [7]Department of General Surgery (Hepatobiliary Surgery), The Affiliated Hospital of Southwest Medical University, Luzhou, China. [8]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China. [9]Academician (Expert) Workstation of Sichuan Province, Luzhou, China. [10]Department of Radiotherapy, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. [11]Clinical Medical College, Southwest Medical University, Luzhou, China. [12]Clinical Skills Center, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
出处：
DOI： 10.3389/fimmu.2022.972503
ISSN：

摘要：
Whether intensity-modulated radiotherapy (IMRT) can enhance the efficacy of the programmed death (PD)-1 inhibitors combined with anti-angiogenic therapy for hepatocellular carcinoma (HCC) is unclear. Therefore, we conducted this multicenter retrospective study to investigate the efficacy of the combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT.From April 2019 to March 2022, a total of 197 patients with HCC [combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT (triple therapy group), 54; PD-1 inhibitors plus anti-angiogenic therapy (control group), 143] were included in our study. Propensity score matching (PSM) was applied to identify two groups with similar baselines. The objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) of the two groups were compared before and after matching.Prior to PSM, the triple therapy group had higher ORR (42.6% vs 24.5%, P = 0.013) and more superior median OS (mOS) (20.1 vs 13.3 months, P = 0.009) and median PFS (mPFS) (8.7 vs 5.4 months, P = 0.001) than the control group. Following PSM, the triple therapy group still exhibited better mPFS (8.7 vs 5.4 months, P = 0.013) and mOS (18.5 vs 12.6 months, P = 0.043) than the control group. However, the ORR of the two groups was similar (40% vs 25%, P = 0.152). No significant difference was observed in the treatment-related adverse events between the two groups (P < 0.05 for all).The combination of PD-1 inhibitors with anti-angiogenic therapy and IMRT for HCC is a promising regimen.Copyright © 2022 Su, Guo, Ma, Wang, Xie, Rao, Zhang, Li, Wen, Li, Yang, Song, Huang, Chi, Gu, Xu, Liu, Chen, Wu, Jiang, Li, Zeng, Wang, Feng, Chen, Yang, Jin, He and Han.

基金：
Project of Science and Technology Department of Sichuan Province (2020JDTD0036) and the Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province (HYX18001).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 2 区 医学
小类 | 2 区 免疫学
最新[2023]版：
大类 | 2 区 医学
小类 | 2 区 免疫学
JCR分区：
出版当年[2022]版：
Q1 IMMUNOLOGY
最新[2023]版：
Q1 IMMUNOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
共同第一作者：
通讯作者：
通讯机构： [1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [8]Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China. [9]Academician (Expert) Workstation of Sichuan Province, Luzhou, China.
推荐引用方式(GB/T 7714)：
Su Ke,Guo Lu,Ma Wenqiong,et al.PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study[J].FRONTIERS IN IMMUNOLOGY.2022,13:doi:10.3389/fimmu.2022.972503.
APA：
Su Ke,Guo Lu,Ma Wenqiong,Wang Jing,Xie Yunchuan...&Han Yunwei.(2022).PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study.FRONTIERS IN IMMUNOLOGY,13,
MLA：
Su Ke,et al."PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study".FRONTIERS IN IMMUNOLOGY 13.(2022)

资源点击量：46407 今日访问量：0 总访问量：3323 更新日期：2024-11-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号